ABOLOGIX is a biopharmaceutical company based in Geneva, Switzerland. It is a spin-out from the laboratories of Prof. Beat Imhof and Prof. Thomas Matthes at the University of Geneva. The lead molecule in the pipeline is H225, a monoclonal antibody targeting JAM - C (Junction Adhesion Molecule C), an endothelial cell adhesion molecule involved in leukocyte transmigration. The company is developing H225 for the treatment of several JAM-C (+) B-cell non Hodgkin´s lymphomas. The Chairman of the Board of ABOLOGIX is Dr. Ignacio Faus, who has more than 20 years of experience in pharmaceutical and biotechnology companies.
View Top Employees from Abologix| Website | http://abologix.com |
| Employees | View employees |
| Founded | 2018 |
| Address | Chemin des Aulx, 14, Plan-les-Ouates, Geneva 1228, CH |
| Phone | +41 22 880 10 10 |
| Industry | Manufacturing General, Discovery Tools (Healthcare), Manufacturing, Biotechnology |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Abologix employee's phone or email?
Abologix Questions
Abologix is based in Plan-les-Ouates, Geneva.
The NAICS codes for Abologix are [325, 3254, 32].
The SIC codes for Abologix are [283, 28, 80].
